Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for GPCR

Stock Name	Structure Therapeutics Inc. American Depositary Shares
Ticker	GPCR(USD) NASDAQ
TYPE	Common Stock
Country	USA

Show aggregate GPCR holdings

News associated with GPCR

Biotech Stocks Rally After Hours On Friday Ahead Of Key Clinical Trial Updates: (RTTNews) - Several clinical-stage biotech companies saw strong after-hours momentum on Friday, driven by upcoming trial data releases and pipeline updates. - 2025-09-22 01:38:16
Sum Up The Parts: ONEQ Could Be Worth $97: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-18 08:11:52
Structure Therapeutics (NASDAQ:GPCR) Raised to “Strong-Buy” at Lifesci Capital: Lifesci Capital upgraded shares of Structure Therapeutics (NASDAQ:GPCR – Free Report) to a strong-buy rating in a research report report published on Monday morning,Zacks.com reports. A number of other equities research analysts have also recently issued reports on GPCR. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 target price on shares of Structure […] - 2025-09-11 02:43:02
Analysts Set Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Target Price at $75.71: Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) has received a consensus rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the […] - 2025-08-25 03:00:58
Alps Advisors Inc. Sells 3,220 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR): Alps Advisors Inc. trimmed its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Free Report) by 7.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 43,080 shares of the company’s stock after selling 3,220 shares during the quarter. Alps Advisors Inc.’s holdings […] - 2025-07-15 06:24:40
Structure Therapeutics Enters Oversold Territory (GPCR): Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me - 2025-07-07 12:55:24
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of “Buy” from Brokerages: Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR – Get Free Report) has been given a consensus recommendation of “Buy” by the seven brokerages that are currently covering the firm, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the […] - 2025-07-03 02:56:55
Structure Therapeutics (NASDAQ:GPCR) Receives Overweight Rating from Cantor Fitzgerald: Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research report issued on Monday,Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price objective points to a potential upside of 190.44% from the stock’s current price. Several […] - 2025-06-25 02:36:50
JMP Securities Reiterates Market Outperform Rating for Structure Therapeutics (NASDAQ:GPCR): Structure Therapeutics (NASDAQ:GPCR – Get Free Report)‘s stock had its “market outperform” rating reissued by equities research analysts at JMP Securities in a research note issued to investors on Monday,Benzinga reports. They presently have a $89.00 target price on the stock. JMP Securities’ target price would suggest a potential upside of 297.68% from the stock’s […] - 2025-06-25 02:36:49
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Price Target at $76.50: Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are presently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year target price among analysts that have issued a report on the […] - 2025-06-11 02:54:42
Bank of America Corp DE Has $1.47 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR): Bank of America Corp DE reduced its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 36.4% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 54,185 shares of the company’s stock after selling 31,021 shares during the quarter. […] - 2025-06-05 04:38:48
Universal Beteiligungs und Servicegesellschaft mbH Makes New $3.09 Million Investment in Structure Therapeutics Inc. (NASDAQ:GPCR): Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 113,992 shares of the company’s stock, valued at approximately $3,091,000. Universal Beteiligungs und Servicegesellschaft mbH owned […] - 2025-06-03 05:10:53
Structure Therapeutics (NASDAQ:GPCR) Price Target Lowered to $75.00 at HC Wainwright: Structure Therapeutics (NASDAQ:GPCR – Free Report) had its price target cut by HC Wainwright from $80.00 to $75.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the stock. A number of other brokerages also recently issued reports on GPCR. William Blair initiated coverage on shares of Structure Therapeutics […] - 2025-05-13 02:42:58
Tower Research Capital LLC TRC Buys 3,549 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR): Tower Research Capital LLC TRC boosted its stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 673.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,076 shares of the company’s stock after purchasing an additional 3,549 shares during the […] - 2025-05-09 05:54:58
Envestnet Asset Management Inc. Acquires 843 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR): Envestnet Asset Management Inc. grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 12.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 7,403 shares of the company’s stock after purchasing an additional 843 shares during the period. Envestnet Asset Management Inc.’s holdings in Structure Therapeutics were worth $201,000 […] - 2025-05-09 04:18:46
Barclays PLC Boosts Stake in Structure Therapeutics Inc. (NASDAQ:GPCR): Barclays PLC lifted its position in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 42.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 115,671 shares of the company’s stock after purchasing an additional 34,533 shares during the quarter. Barclays PLC’s […] - 2025-04-30 05:12:48
Analysts Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29: Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have earned an average rating of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have issued a report on […] - 2025-04-22 02:34:58
Bank of Montreal Can Purchases 3,671 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR): Bank of Montreal Can lifted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 7.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,173 shares of the company’s stock after buying an additional 3,671 shares during the quarter. […] - 2025-04-18 05:08:54
Alliancebernstein L.P. Sells 16,372 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR): Alliancebernstein L.P. trimmed its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 10.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,825 shares of the company’s stock after selling 16,372 shares during the quarter. Alliancebernstein L.P.’s holdings in […] - 2025-04-15 04:52:54
American Century Companies Inc. Purchases 67,325 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR): American Century Companies Inc. increased its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 12.3% in the 4th quarter, HoldingsChannel reports. The fund owned 612,616 shares of the company’s stock after acquiring an additional 67,325 shares during the period. American Century Companies Inc.’s holdings in Structure Therapeutics were worth $16,614,000 as […] - 2025-04-01 05:04:51
Natixis Advisors LLC Reduces Position in Structure Therapeutics Inc. (NASDAQ:GPCR): Natixis Advisors LLC decreased its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 45.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,459 shares of the company’s stock after selling 12,216 shares during the quarter. Natixis Advisors LLC’s […] - 2025-03-28 06:04:49
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus Target Price from Brokerages: Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research firms that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in […] - 2025-03-28 03:34:46
Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Bought by M&T Bank Corp: M&T Bank Corp raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 100.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 18,110 shares of the company’s stock after purchasing an additional 9,055 shares during the period. […] - 2025-03-14 06:54:57
Structure Therapeutics Inc. (NASDAQ:GPCR) Receives $81.29 Consensus PT from Brokerages: Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned a consensus rating of “Buy” from the eight research firms that are covering the company, MarketBeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have updated their coverage on […] - 2025-03-05 04:58:44
abrdn plc Has $4.65 Million Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR): abrdn plc lessened its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) by 21.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 171,388 shares of the company’s stock after selling 45,695 shares during the quarter. abrdn plc’s holdings in […] - 2025-02-10 16:42:59
Spire Wealth Management Makes New $243,000 Investment in Structure Therapeutics Inc. (NASDAQ:GPCR): Spire Wealth Management bought a new stake in Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund bought 8,949 shares of the company’s stock, valued at approximately $243,000. Several other hedge funds and other institutional investors also recently made changes to their positions in GPCR. Point72 Asset Management […] - 2025-02-07 07:04:12
Brokerages Set Structure Therapeutics Inc. (NASDAQ:GPCR) Target Price at $81.29: Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the […] - 2025-02-06 04:06:45
Structure Therapeutics Inc. (NASDAQ:GPCR) Short Interest Update: Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,750,000 shares, a growth of 5.8% from the December 31st total of 10,160,000 shares. Approximately 19.8% of the company’s shares are sold short. […] - 2025-02-03 04:12:44

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) GPCR holdings

Date	Number of GPCR Shares Held	Base Market Value of GPCR Shares	Local Market Value of GPCR Shares	Change in GPCR Shares Held	Change in GPCR Base Value	Current Price per GPCR Share Held	Previous Price per GPCR Share Held
2025-11-11 (Tuesday)	38,236	USD 1,333,098	USD 1,333,098	0	USD 36,898	USD 34.865	USD 33.9
2025-11-10 (Monday)	38,236	USD 1,296,200	USD 1,296,200	98	USD 43,748	USD 33.9	USD 32.84
2025-11-07 (Friday)	38,138	USD 1,252,452	USD 1,252,452	0	USD -24,027	USD 32.84	USD 33.47
2025-11-06 (Thursday)	38,138	USD 1,276,479	USD 1,276,479	98	USD 51,211	USD 33.47	USD 32.21
2025-11-05 (Wednesday)	38,040	USD 1,225,268	USD 1,225,268	0	USD -68,472	USD 32.21	USD 34.01
2025-11-04 (Tuesday)	38,040	USD 1,293,740	USD 1,293,740	98	USD 50,760	USD 34.01	USD 32.76
2025-11-03 (Monday)	37,942	USD 1,242,980	USD 1,242,980	0	USD -21,247	USD 32.76	USD 33.32
2025-10-31 (Friday)	37,942	USD 1,264,227	USD 1,264,227	0	USD 41,736	USD 33.32	USD 32.22
2025-10-30 (Thursday)	37,942	USD 1,222,491	USD 1,222,491	490	USD 115,035	USD 32.22	USD 29.57
2025-10-29 (Wednesday)	37,452	USD 1,107,456	USD 1,107,456	196	USD 28,895	USD 29.57	USD 28.95
2025-10-28 (Tuesday)	37,256	USD 1,078,561	USD 1,078,561	0	USD 11,177	USD 28.95	USD 28.65
2025-10-27 (Monday)	37,256	USD 1,067,384	USD 1,067,384	0	USD 84,198	USD 28.65	USD 26.39

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of GPCR by Blackrock for IE00BDZVHG35

Show aggregate share trades of GPCR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 98 35.130 33.001 33.214 USD 3,255 25.80
2025-11-06 BUY 98 33.860 32.430 32.573 USD 3,192 25.72
2025-11-04 BUY 98 34.500 32.640 32.826 USD 3,217 25.63
2025-10-30 BUY 490 32.350 30.240 30.451 USD 14,921 25.51
2025-10-29 BUY 196 29.570 29.800 29.777 USD 5,836 25.49
2025-10-22 SELL -392 26.660 27.000 26.966 USD -10,571 25.44 Loss of -600 on sale
2025-10-20 BUY 196 27.870 28.255 28.216 USD 5,530 25.41
2025-10-17 BUY 490 27.380 28.560 28.442 USD 13,937 25.40
2025-10-15 BUY 784 29.230 31.080 30.895 USD 24,222 25.38
2025-10-03 BUY 686 27.280 27.500 27.478 USD 18,850 25.34
2025-10-02 BUY 98 26.620 26.755 26.741 USD 2,621 25.33
2025-09-30 BUY 196 28.000 28.070 28.063 USD 5,500 25.31
2025-09-26 BUY 196 25.000 26.150 26.035 USD 5,103 25.31
2025-09-25 BUY 196 24.990 25.760 25.683 USD 5,034 25.31
2025-09-18 BUY 103 23.230 23.470 23.446 USD 2,415 25.33
2025-09-17 BUY 309 21.650 22.520 22.433 USD 6,932 25.35
2025-07-17 SELL -204 19.530 20.250 20.178 USD -4,116 25.50 Profit of 1,085 on sale
2025-07-11 SELL -824 19.010 19.890 19.802 USD -16,317 25.66 Profit of 4,826 on sale
2025-07-02 BUY 5,665 20.440 21.400 21.304 USD 120,687 25.82
2025-06-25 BUY 204 21.790 22.420 22.357 USD 4,561 25.95
2025-06-20 BUY 1,321 21.730 22.330 22.270 USD 29,419 26.03
2025-06-11 BUY 196 22.720 24.050 23.917 USD 4,688 26.27
2025-06-10 BUY 196 21.830 21.890 21.884 USD 4,289 26.30
2025-06-04 SELL -98 22.000 22.976 22.878 USD -2,242 26.46 Profit of 351 on sale
2025-04-23 BUY 98 23.320 24.450 24.337 USD 2,385 27.04
2025-04-10 SELL -784 15.050 15.580 15.527 USD -12,173 27.78 Profit of 9,607 on sale
2025-04-08 SELL -98 14.150 15.450 15.320 USD -1,501 28.08 Profit of 1,251 on sale
2025-04-07 SELL -98 14.310 15.530 15.408 USD -1,510 28.24 Profit of 1,258 on sale
2025-04-04 SELL -495 15.120 15.950 15.867 USD -7,854 28.40 Profit of 6,202 on sale
2025-04-01 BUY 404 15.790 17.275 17.126 USD 6,919 28.69
2025-03-31 SELL -297 17.310 19.220 19.029 USD -5,652 28.82 Profit of 2,909 on sale
2025-03-21 BUY 1,294 20.970 21.900 21.807 USD 28,218 29.49
2025-03-14 SELL -1,520 21.050 21.490 21.446 USD -32,598 30.04 Profit of 13,068 on sale
2025-03-07 SELL -188 22.620 23.290 23.223 USD -4,366 30.73 Profit of 1,411 on sale
2025-03-04 SELL -94 22.490 22.800 22.769 USD -2,140 31.10 Profit of 783 on sale
2025-02-25 BUY 190 21.090 21.500 21.459 USD 4,077 31.89
2025-02-19 SELL -94 23.850 23.890 23.886 USD -2,245 32.55 Profit of 814 on sale
2025-02-13 BUY 282 24.370 24.590 24.568 USD 6,928 33.23
2025-02-12 BUY 94 24.330 24.860 24.807 USD 2,332 33.41
2025-02-11 BUY 376 24.800 25.480 25.412 USD 9,555 33.59
2024-12-30 SELL -3,307 26.630 28.844 28.623 USD -94,655 35.84 Profit of 23,856 on sale
2024-11-18 SELL -1,530 31.750 33.920 33.703 USD -51,566 38.67 Profit of 7,599 on sale
2024-11-08 SELL -102 38.020 38.580 38.524 USD -3,929 38.84 Profit of 32 on sale
2024-10-21 SELL -103 38.820 39.705 39.617 USD -4,080 0.00 Loss of -4,080 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	98	35.130	33.001	33.214	USD 3,255	25.80
2025-11-06	BUY	98	33.860	32.430	32.573	USD 3,192	25.72
2025-11-04	BUY	98	34.500	32.640	32.826	USD 3,217	25.63
2025-10-30	BUY	490	32.350	30.240	30.451	USD 14,921	25.51
2025-10-29	BUY	196	29.570	29.800	29.777	USD 5,836	25.49
2025-10-22	SELL	-392	26.660	27.000	26.966	USD -10,571	25.44 Loss of -600 on sale
2025-10-20	BUY	196	27.870	28.255	28.216	USD 5,530	25.41
2025-10-17	BUY	490	27.380	28.560	28.442	USD 13,937	25.40
2025-10-15	BUY	784	29.230	31.080	30.895	USD 24,222	25.38
2025-10-03	BUY	686	27.280	27.500	27.478	USD 18,850	25.34
2025-10-02	BUY	98	26.620	26.755	26.741	USD 2,621	25.33
2025-09-30	BUY	196	28.000	28.070	28.063	USD 5,500	25.31
2025-09-26	BUY	196	25.000	26.150	26.035	USD 5,103	25.31
2025-09-25	BUY	196	24.990	25.760	25.683	USD 5,034	25.31
2025-09-18	BUY	103	23.230	23.470	23.446	USD 2,415	25.33
2025-09-17	BUY	309	21.650	22.520	22.433	USD 6,932	25.35
2025-07-17	SELL	-204	19.530	20.250	20.178	USD -4,116	25.50 Profit of 1,085 on sale
2025-07-11	SELL	-824	19.010	19.890	19.802	USD -16,317	25.66 Profit of 4,826 on sale
2025-07-02	BUY	5,665	20.440	21.400	21.304	USD 120,687	25.82
2025-06-25	BUY	204	21.790	22.420	22.357	USD 4,561	25.95
2025-06-20	BUY	1,321	21.730	22.330	22.270	USD 29,419	26.03
2025-06-11	BUY	196	22.720	24.050	23.917	USD 4,688	26.27
2025-06-10	BUY	196	21.830	21.890	21.884	USD 4,289	26.30
2025-06-04	SELL	-98	22.000	22.976	22.878	USD -2,242	26.46 Profit of 351 on sale
2025-04-23	BUY	98	23.320	24.450	24.337	USD 2,385	27.04
2025-04-10	SELL	-784	15.050	15.580	15.527	USD -12,173	27.78 Profit of 9,607 on sale
2025-04-08	SELL	-98	14.150	15.450	15.320	USD -1,501	28.08 Profit of 1,251 on sale
2025-04-07	SELL	-98	14.310	15.530	15.408	USD -1,510	28.24 Profit of 1,258 on sale
2025-04-04	SELL	-495	15.120	15.950	15.867	USD -7,854	28.40 Profit of 6,202 on sale
2025-04-01	BUY	404	15.790	17.275	17.126	USD 6,919	28.69
2025-03-31	SELL	-297	17.310	19.220	19.029	USD -5,652	28.82 Profit of 2,909 on sale
2025-03-21	BUY	1,294	20.970	21.900	21.807	USD 28,218	29.49
2025-03-14	SELL	-1,520	21.050	21.490	21.446	USD -32,598	30.04 Profit of 13,068 on sale
2025-03-07	SELL	-188	22.620	23.290	23.223	USD -4,366	30.73 Profit of 1,411 on sale
2025-03-04	SELL	-94	22.490	22.800	22.769	USD -2,140	31.10 Profit of 783 on sale
2025-02-25	BUY	190	21.090	21.500	21.459	USD 4,077	31.89
2025-02-19	SELL	-94	23.850	23.890	23.886	USD -2,245	32.55 Profit of 814 on sale
2025-02-13	BUY	282	24.370	24.590	24.568	USD 6,928	33.23
2025-02-12	BUY	94	24.330	24.860	24.807	USD 2,332	33.41
2025-02-11	BUY	376	24.800	25.480	25.412	USD 9,555	33.59
2024-12-30	SELL	-3,307	26.630	28.844	28.623	USD -94,655	35.84 Profit of 23,856 on sale
2024-11-18	SELL	-1,530	31.750	33.920	33.703	USD -51,566	38.67 Profit of 7,599 on sale
2024-11-08	SELL	-102	38.020	38.580	38.524	USD -3,929	38.84 Profit of 32 on sale
2024-10-21	SELL	-103	38.820	39.705	39.617	USD -4,080	0.00 Loss of -4,080 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of GPCR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	125,007	0	243,579	51.3%
2025-09-18	113,684	0	380,195	29.9%
2025-09-17	206,494	0	416,951	49.5%
2025-09-16	119,540	0	335,038	35.7%
2025-09-15	121,400	0	470,215	25.8%
2025-09-12	184,589	0	967,720	19.1%
2025-09-11	75,680	0	218,265	34.7%
2025-09-10	113,432	0	280,608	40.4%
2025-09-09	149,425	0	530,291	28.2%
2025-09-08	179,625	0	356,770	50.3%
2025-09-05	284,952	1	719,574	39.6%
2025-09-04	310,062	121	461,434	67.2%
2025-09-03	255,187	2,004	5,246,037	4.9%
2025-09-02	133,124	800	334,020	39.9%
2025-08-29	92,696	0	207,708	44.6%
2025-08-28	65,370	0	148,255	44.1%
2025-08-27	66,326	6	177,761	37.3%
2025-08-26	60,632	0	147,615	41.1%
2025-08-25	47,665	2	107,723	44.2%
2025-08-22	94,929	0	244,219	38.9%
2025-08-21	74,695	0	513,146	14.6%
2025-08-20	88,021	0	245,285	35.9%
2025-08-19	203,596	1,521	501,385	40.6%
2025-08-18	130,126	365	373,926	34.8%
2025-08-15	80,300	15	267,100	30.1%
2025-08-14	67,897	0	153,720	44.2%
2025-08-13	169,999	25	696,661	24.4%
2025-08-12	373,045	0	582,396	64.1%
2025-08-11	128,769	48	462,698	27.8%
2025-08-08	149,229	0	696,910	21.4%
2025-08-07	797,447	0	1,423,379	56.0%
2025-08-06	162,717	0	554,309	29.4%
2025-08-05	118,219	188	312,154	37.9%
2025-08-04	113,151	5,281	216,752	52.2%
2025-08-01	93,037	0	300,151	31.0%
2025-07-31	180,291	7	454,281	39.7%
2025-07-30	41,257	22	184,249	22.4%
2025-07-29	97,033	0	339,170	28.6%
2025-07-28	120,256	0	348,046	34.6%
2025-07-25	57,904	0	227,047	25.5%
2025-07-24	43,290	200	251,155	17.2%
2025-07-23	40,809	2,837	192,700	21.2%
2025-07-22	119,519	631	347,524	34.4%
2025-07-21	70,620	16	659,103	10.7%
2025-07-18	78,451	0	1,268,743	6.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE